AstraZeneca and Alexion’s self-administered generalized myasthenia gravis treatment, Klygefa (gefurulimab), received FDA approval, entering a crowded market for gMG. The once-weekly therapy is designed for anti-acetylcholine receptor antibody-positive patients, reshaping competitive dynamics in a segment where dosing convenience and response durability have become key differentiators.
Get the Daily Brief